Jim Simons
NTLA icon

Jim Simons’s Intellia Therapeutics NTLA Stock Holding History

Jim Simons’s Portfolio NTLA Stock Details NTLA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-1,672,700
Closed -$15M – 3547
2025
Q4 		$15M Buy
1,672,700
+1,021,700
+157% +$14.1M 0.02% 732
2025
Q3 		$11.2M Sell
651,000
-25,900
-4% -$319K 0.01% 1037
2025
Q2 		$6.35M Buy
+676,900
New +$5.56M 0.01% 1368
2025
Q1 		– Sell
-98,700
Closed -$1.15M – 3720
2024
Q4 		$1.15M Buy
+98,700
New +$1.54M ﹤0.01% 2421
2024
Q3 		– Sell
-38,700
Closed -$866K – 3775
2024
Q2 		$866K Buy
+38,700
New +$921K ﹤0.01% 2400
2024
Q1 		– Sell
-13,397
Closed -$408K – 3953
2023
Q4 		$408K Buy
+13,397
New +$385K ﹤0.01% 2864
2023
Q2 		– Sell
-16,554
Closed -$617K – 4162
2023
Q1 		$617K Buy
+16,554
New +$649K ﹤0.01% 2774
2022
Q3 		– Sell
-119,600
Closed -$6.19M – 4302
2022
Q2 		$6.19M Buy
+119,600
New +$6.07M 0.01% 1403
2020
Q3 		– Sell
-41,000
Closed -$862K – 3581
2020
Q2 		$862K Buy
+41,000
New +$697K ﹤0.01% 2616
2020
Q1 		– Sell
-36,700
Closed -$538K – 3677
2019
Q4 		$538K Buy
+36,700
New +$511K ﹤0.01% 2879
2019
Q3 		– Sell
-164,600
Closed -$2.69M – 3614
2019
Q2 		$2.69M Buy
+164,600
New +$2.59M ﹤0.01% 2175
2019
Q1 		– Sell
-228,000
Closed -$3.11M – 3617
2018
Q4 		$3.11M Buy
+228,000
New +$4.24M ﹤0.01% 2012
2017
Q3 		– Sell
-19,200
Closed -$307K – 3308
2017
Q2 		$307K Buy
+19,200
New +$268K ﹤0.01% 2902

Other funds holding NTLA

AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
RP
Regeneron Pharmaceuticals Tarrytown, New York $177M AUM 9.82% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Jim Simons's NTLA Position: Q1 2026 in Review

Jim Simons sold out of Intellia Therapeutics (NTLA) in Q1 2026, closing a stake of 1,672,700 shares — an estimated $15M sold.

Jim Simons first reported a position in NTLA in Q2 2017 and held it in 13 quarters. The position peaked at $15M in Q4 2025. 303 funds tracked by Wall St. Rank hold NTLA as of Q1 2026.

  • Jim Simons reported no remaining Intellia Therapeutics position as of Q1 2026 after selling out during the quarter.
  • Jim Simons sold 1,672,700 Intellia Therapeutics shares in Q1 2026, an estimated $15M.
  • Jim Simons first reported a position in Intellia Therapeutics in Q2 2017 and held it in 13 quarters.
  • Jim Simons's Intellia Therapeutics position peaked at $15M in Q4 2025.
  • 303 funds tracked by Wall St. Rank held Intellia Therapeutics as of Q1 2026.

Based on Renaissance Technologies's 13F filing for Q1 2026, filed 14 May 2026.